A Novel Non-Invasive Ocular Delivery Platform DOI Open Access
Jenny Wang,

Nonna Snider

Опубликована: Авг. 14, 2023

To this day, use of oily eye drops and non-invasive retinal delivery remains a major challenge. Oily usually cause ocular irritation interfere with normal function the eye, while injections for drug significant adverse effects high burden on healthcare system. Here authors report novel topical Non-Invasive Ocular Delivery Platform (NIODP) through periorbital skin efficiency anterior posterior in non-human primate model (NHP). A single dose about 7mg JV-MD2 (omega-3 DHA) via NIODP reached retina at Cmax 111µg/g cornea 66µg/g. also delivered JV-DE1, an anti-inflammatory agent development dry diseases, as efficiently did to segments NHP. The seems transport candidates pathway conjunctiva/sclera eye. method has potential reshape landscape delivery, especially where success treatment lies tolerability bioavailability drugs target tissue.

Язык: Английский

Apolipoprotein-ε4 allele (APOE-ε4) as a Mediator of Cognitive Loss and Dementia in Long COVID-19 DOI
Kenneth Maiese

Current Neurovascular Research, Год журнала: 2022, Номер 19(5), С. 435 - 439

Опубликована: Окт. 1, 2022

Язык: Английский

Процитировано

9

Ferroptosis, Iron Metabolism, and Forkhead Transcription Factors (FoxOs) DOI
Kenneth Maiese

Current Neurovascular Research, Год журнала: 2023, Номер 20(3), С. 291 - 295

Опубликована: Июль 7, 2023

Язык: Английский

Процитировано

3

Discovery and Potential Utility of a Novel Non-Invasive Ocular Delivery Platform DOI Creative Commons
Weizhen Wang,

Nonna Snider

Pharmaceutics, Год журнала: 2023, Номер 15(9), С. 2344 - 2344

Опубликована: Сен. 19, 2023

To this day, the use of oily eye drops and non-invasive retinal delivery remain a major challenge. Oily usually cause ocular irritation interfere with normal functioning eye, while injections for drug significant adverse effects high burden on healthcare system. Here, authors report novel topical platform (NIODP) through periorbital skin high-efficiency anterior posterior in non-human primate model (NHP). A single dose about 7 mg JV-MD2 (omega 3 DHA) was delivered via NIODP reached retina at Cmax 111 µg/g cornea 66 µg/g. The also JV-DE1, an anti-inflammatory agent development dry diseases, as efficiently did to segments NHP. seems transport candidates corneal pathway conjunctiva/sclera eye. method has potential reshape landscape delivery. This is especially case delivery, where success treatment lies tolerability bioavailability drugs target tissue.

Язык: Английский

Процитировано

2

Sensory Profiles and Technological Deficits: Classification, Relevance, and Gaps DOI
James Hutson, Piper Hutson,

Morgan Harper-Nichols

и другие.

Опубликована: Янв. 1, 2024

The chapter provides an analysis of the diverse range sensory experiences and challenges in addressing them with current technology. Opening a discussion on how cultural spiritual beliefs shape perceptions, uses insights from various cultures, including Berinmo people. It then delves into aesthetic disabilities beyond visual perception, such as face blindness, dyschromatopsia, dyscalculia, synesthesia, exploring their unique impacts artistic interpretation. also tackles cross-modal challenges, highlighting conditions like anosmia agnosia, implications for experiencing art. Emphasizing neurodiversity, it examines neurodivergent individuals, particularly those spectrum, have distinct preferences responses to Aphantasia's role experience is discussed, absence mental imagery influences art perception creation. Finally, identifies key gaps technological applications, discussing issues ableism technologies need more inclusive adaptable tools. concludes by therapeutic adaptive color therapy adaptations museums, emphasizing importance developing that cater broad spectrum preferences. This crucial intricate relationship between experiences, technology enhancing engagement.

Язык: Английский

Процитировано

0

Investigating the relationship between blood metabolites and diabetic retinopathy using two-sample mendelian randomization and in vivo validation DOI Creative Commons

Yihuan Zeng,

Guangmeng Mo,

Xiaoyv Wang

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Окт. 3, 2024

Язык: Английский

Процитировано

0

Role of Apoptosis in Diabetes: Therapeutic Targets and Strategies DOI
Sourav Bar, Soumik Dhara, Satyajit Halder

и другие.

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

0

mTOR Downregulation Promotes Anti-Inflammatory Responses via the CCL3-CCR5 Axis in Hypoxic Retinopathy DOI Creative Commons

Tae Kwon Moon,

Insug Kang, Kyoung Jin Lee

и другие.

Molecular Therapy — Methods & Clinical Development, Год журнала: 2024, Номер 33(1), С. 101404 - 101404

Опубликована: Дек. 31, 2024

Язык: Английский

Процитировано

0

Diabetic Retinopathy and the Extracellular Vesicles. DOI Open Access

Kuppamuthu Dharmalingam,

Kim Ramasamy

Опубликована: Июнь 13, 2023

Diabetes and diabetes-induced micro macrovascular complications are major causes of healthcare problems. The extracellular vesicles produced by all cells from organisms. They shown to have properties the producer also reflect host physiology pathology. Since EVs represent cellular state they excellent biomarkers. In this review, we will focus on Neuro Vascular Unit eye as well extraocular in onset progression diabetic retinopathy. A brief account use these nanovesicles personalised medicine is given.

Язык: Английский

Процитировано

1

A Novel Non-Invasive Ocular Delivery Platform DOI Open Access
Jenny Wang,

Nonna Snider

Опубликована: Авг. 14, 2023

To this day, use of oily eye drops and non-invasive retinal delivery remains a major challenge. Oily usually cause ocular irritation interfere with normal function the eye, while injections for drug significant adverse effects high burden on healthcare system. Here authors report novel topical Non-Invasive Ocular Delivery Platform (NIODP) through periorbital skin efficiency anterior posterior in non-human primate model (NHP). A single dose about 7mg JV-MD2 (omega-3 DHA) via NIODP reached retina at Cmax 111µg/g cornea 66µg/g. also delivered JV-DE1, an anti-inflammatory agent development dry diseases, as efficiently did to segments NHP. The seems transport candidates pathway conjunctiva/sclera eye. method has potential reshape landscape delivery, especially where success treatment lies tolerability bioavailability drugs target tissue.

Язык: Английский

Процитировано

1